Did Ozempic cause a woman's death from gastroparesis?

What did @newsnationnow actually say?

Attorney Jonathan Orent told NewsNation that his client Marsha Ettinghoff died after six months on Ozempic. He says she experienced "days and days of uncontrolled vomiting" and aspirated while being driven to the hospital. His core legal claim: the risks "could have been warned of" and "should have been warned of," and that recent FDA action validates his lawsuits.

This is a news clip of a plaintiff's attorney speaking on behalf of a grieving family. That context matters enormously. Orent is not a physician, not a pharmacologist, and he has a financial and legal stake in framing this story a specific way. That doesn't make him wrong, but it means the claims deserve scrutiny before they reach 156,000 viewers as implied fact.

Does the science back this up?

Partially, yes. Gastroparesis is a real, documented risk with GLP-1 receptor agonists like semaglutide. The FDA added warnings about it. But the leap from "this is a known risk" to "this specific death was caused by inadequately warned gastroparesis" is a legal argument, not a medical conclusion.

A 2023 study by Sodhi et al. published in JAMA found that GLP-1 receptor agonists were associated with a significantly higher risk of gastroparesis compared to bupropion-naltrexone among patients without diabetes (adjusted hazard ratio 3.67). That finding is real and important. However, the FDA's label for Ozempic has included warnings about nausea, vomiting, and gastrointestinal adverse events since its initial approval. Whether those warnings were sufficiently specific about severity, duration, or the aspiration risk that follows prolonged vomiting is where legitimate medical and legal debate lives. The claim that there was zero warning is not accurate. The claim that warnings were inadequate is at least arguable.

What did they get wrong (or right)?

They got the basic pharmacology right: semaglutide does slow gastric emptying, and that mechanism can produce severe, prolonged nausea and vomiting in some patients. Aspiration from intractable vomiting is a known, serious medical complication. None of that is fabricated.

What's missing or overstated: The clip frames this as though Ozempic's risks were entirely hidden from patients. That's not accurate. Novo Nordisk's prescribing information lists gastrointestinal adverse events prominently. The FDA did update gastroparesis language in 2023, but that update reflects evolving post-market data, not evidence of deliberate concealment. Also absent from this segment is any mention of whether Marsha had underlying conditions, what dose she was on, whether she sought medical attention before the crisis, or whether her prescribing provider discussed GI risk management. Those details are not irrelevant to the causal story being told here.

What should you actually know?

If you are taking a GLP-1 medication and you experience persistent, severe vomiting that lasts more than 24 hours, that is a medical emergency signal, not something to wait out at home. Aspiration pneumonia from vomiting is a serious, potentially fatal complication, and it does not require gastroparesis as a formal diagnosis to occur.

The FDA's 2023 label update for semaglutide products added more explicit gastroparesis language following post-market safety signals. That update was driven by data, including the Sodhi et al. JAMA findings and FDA adverse event reports. It does not prove that prior warnings were legally deficient, but it does confirm that the risk is real and was underappreciated in early labeling. If you are concerned about your current GLP-1 regimen, talk to your prescriber. Do not stop abruptly based on a TikTok news clip. The risk of untreated obesity and type 2 diabetes is also real and documented.

What's the bottom line on this legal framing?

Plaintiff attorneys arguing failure-to-warn cases against pharmaceutical companies is not new, and it is not inherently dishonest. Sometimes those lawsuits surface genuine safety gaps. But broadcasting a grieving husband's account and an attorney's legal theory as a fact-based news story, without medical expert commentary or caveats, does a disservice to viewers who may be managing their own GLP-1 prescriptions right now. The science says gastroparesis is a real risk. It does not say Ozempic killed Marsha Ettinghoff. Those are different claims, and conflating them is how medical panic spreads.